Edge Financial Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,791
Closed -$241K 114
2024
Q4
$241K Buy
2,791
+25
+0.9% +$2.26K 0.22% 87
2024
Q3
$263K Buy
+2,766
New +$263K 0.23% 81
2024
Q2
Sell
-2,739
Closed -$248K 122
2024
Q1
$248K Buy
+2,739
New +$240K 0.22% 117

Other funds holding PPH

Edge Financial Advisors's PPH Position: Q1 2025 in Review

Edge Financial Advisors sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2025, closing a stake of 2,791 shares — an estimated $241K sold.

Edge Financial Advisors first reported a position in PPH in Q1 2024 and held it in 3 quarters. The position peaked at $263K in Q3 2024. 136 funds tracked by Wall St. Rank hold PPH as of Q1 2025.

  • Edge Financial Advisors reported no remaining VanEck Pharmaceutical ETF position as of Q1 2025 after selling out during the quarter.
  • Edge Financial Advisors sold 2,791 VanEck Pharmaceutical ETF shares in Q1 2025, an estimated $241K.
  • Edge Financial Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2024 and held it in 3 quarters.
  • Edge Financial Advisors's VanEck Pharmaceutical ETF position peaked at $263K in Q3 2024.
  • 136 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2025.

Based on Edge Financial Advisors's 13F filing for Q1 2025, filed 18 Apr 2025.